Synthesis, structure and in vitro pharmacological evaluation of a novel 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (2'-methylbenzoyl) hydrazone bridged copper(II) coordination polymer.
A novel ligand bridged copper(II) coordination polymer, [Cu(HL)(NO3)]n has been synthesized by reacting 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (2'-methylbenzoyl) hydrazone (H2L) with Cu(NO3)2·3H2O, and characterized by X-ray diffraction studies. The DNA interaction studies revealed that the compounds could interact with CT-DNA through intercalation. A gel electrophoresis assay demonstrated the ability of the complex to cleave the pBR322 plasmid DNA. The protein binding studies indicated that the complex exhibited strong binding affinities. Investigations of antioxidative properties showed that the polymeric Cu(II) complex has strong radical scavenging potencies. The cytotoxic effect of the compounds showed that the polymeric complex exhibited excellent anticancer activity against Hep G2, and A431 cells which is six to ten times better than that of well-known commercial anticancer drug, cisplatin.